Medical drug program updates
You can refer to the chart below to review changes and updates related to CarePartners of Connecticut's prior authorization and coverage program for medical drugs.
Updates to existing prior authorization programs | ||
Drug/MNG
| Policy and additional information | Effective date
|
Abecma (idecabtagene vicleucel)
| Removal of language stating that Abecma is only available through a restricted Risk Evaluation and Mitigation Strategy (REMS) program. Clarification of limitation related to immunosuppressive therapy to note that this limitation applies if the therapy is likely to interfere with T cell function. | 9/1/2025 |
Breyanzi (lisocabtagene maraleucel)
| Removal of language stating that Breyanzi is only available through a restricted Risk Evaluation and Mitigation Strategy (REMS) program. Clarification of limitation related to immunosuppressive therapy to note that this limitation applies if the therapy is likely to interfere with T cell function. | 9/1/2025 |
Carvykti (ciltacabtagene autoleucel)
| Removal of language stating that Carvykti is only available through a restricted Risk Evaluation and Mitigation Strategy (REMS) program. Clarification of limitation related to immunosuppressive therapy to note that this limitation applies if the therapy is likely to interfere with T cell function. | 9/1/2025 |
| Removal of language stating that Kymriah is only available through a restricted Risk Evaluation and Mitigation Strategy (REMS) program. Clarification of limitation related to immunosuppressive therapy to note that this limitation applies if the therapy is likely to interfere with T cell function. | 9/1/2025 |
Tecartus (brexucabtagene autoleucel)
| Removal of language stating that Tecartus is only available through a restricted Risk Evaluation and Mitigation Strategy (REMS) program. Clarification of limitation related to immunosuppressive therapy to note that this limitation applies if the therapy is likely to interfere with T cell function. | 9/1/2025 |
Yescarta (axicabtagene ciloleucel)
| Removal of language stating that Yescarta is only available through a restricted Risk Evaluation and Mitigation Strategy (REMS) program. Clarification of limitation related to immunosuppressive therapy to note that this limitation applies if the therapy is likely to interfere with T cell function. | 9/1/2025 |